VBLT News and Press, Vascular Biogenics Ltd. From 07/20/22

Vascular Biogenics ( NASDAQ: VBLT ) was downgraded to Neutral from Buy at H.C. Wainwright after the company's ovarian cancer drug ofra-vec failed a phase 3 trial. Vascular stock fell post-market July 19 following the news. As of premarket July 20, VBLT shares have shed -...

VBL Therapeutics ( NASDAQ: VBLT ) on Tuesday said its phase 3 trial of its ovarian cancer treatment ofra-vec did not meet its main goals. The late-stage trial, called OVAL, did not meet the primary endpoints of achieving a statistically significant improvement in progr...

TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced top-line data from the Phase 3 OVAL clinical trial of ofra-vec (ofranergene oba...

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced tha...

Vascular Biogenics Ltd. (VBLT) Q1 2022 Earnings Conference Call May 17, 2022, 08:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dror Harats - CEO Sam Backenroth - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Kevin DeGeeter - Oppenheimer RK Ramakant...

VBL Therapeutics press release (NASDAQ:VBLT): Q1 GAAP EPS of -$0.13 misses by $0.01. Revenue of $0.11M (-38.9% Y/Y) misses by $0.09M. At March 31, 2022, VBL had cash, cash equivalents, short-term bank deposits and restricted bank deposits of $44.8M. VBL expects that its cash, cash equivalents...

OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV, Israel and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (...

VBL Therapeutics (NASDAQ:VBLT) is scheduled to announce Q1 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is -$0.12 (flat Y/Y) and the consensus Revenue Estimate is $0.2M (+11.1% Y/Y). Over the last 1 year, VBLT has beaten EPS estimates 50% of the time a...

AER, ALLT, BPTH, OTCPK:ENGIY, OTCQB:GAXY, HD, HUYA, OTCQX:IMBBY, JD, JMIA, KMDA, MDWD, OBSV, ONON, PTN, REE, RSKD, SE, VBLT, VOD, WMT, XNET For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Tuesday's open

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today ann...